Lowe's Companies, Inc. (NYSE: LOW) reported adjusted earnings per share (EPS) for the first quarter of fiscal 2023, amounting to $3.67 and surpassing the consensus estimate of $3.44. 

Based on factors such as higher-than-expected lumber deflation and lower-than-anticipated DIY discretionary sales, Lowe's is revising its outlook for the operating results of the full year 2023. The company now expects total sales to be approximately $87 to $89 billion, compared to the previous estimate of $88 to $90 billion. Additionally, the adjusted diluted earnings per share projection has been updated to $13.20 to $13.60, adjusted from the previous range of $13.60 to $14.00.

$LOW is currently trading at $200.19 in pre-market, experiencing a decrease of $2.96 (-1.46%) before the market opens.

Achieve Life Sciences, Inc. (Nasdaq: ACHV) has announced positive topline results from the Phase 3 ORCA-3 trial of cytisinicline, a medication aimed at helping people quit smoking. The trial results align with the previously reported Phase 3 ORCA-2 study, demonstrating a statistically significant benefit of cytisinicline over a placebo in smoking cessation efforts.

The treatment with cytisinicline was well-tolerated, with low rates of adverse events reported. The study showed a 6x increase in the odds of continuous smoking abstinence at 6 months for those receiving cytisinicline compared to the placebo.

In pre-market, $ACHV is currently trading at $8.38, reflecting a $0.23 increase (+2.82) prior to the market opening.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)